Related Experiment Video
Updated: May 27, 2025

10:39
Using Mouse Mammary Tumor Cells to Teach Core Biology Concepts: A Simple Lab Module
Published on: June 18, 2015
13.1K
Oral SERDs: Transforming the treatment of advanced breast cancer-Insights from EMBER-3
Manuel Alva-Bianchi1, Rodrigo Sánchez-Bayona2, Eva Ciruelos2
1Hospital Universitario 12 de Octubre, Madrid, Spain.
Med (New York, N.Y.)
|February 15, 2025
Abstract:
The phase 3 EMBER-3 trial1 demonstrated that when compared to standard therapy, imlunestrant improved progression-free survival (PFS) in advanced ER+/HER2- breast cancer with ESR1 mutations. When combined with abemaciclib, it significantly improved PFS for the entire population. However, the absence of a biomarker-based control group limits broader conclusions, highlighting the need for trials incorporating specific standards in ER+/HER2- breast cancer.

